<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Gastrointest Surg</journal-id>
      <journal-title>Journal of Gastrointestinal Surgery</journal-title>
      <issn pub-type="ppub">1091-255X</issn>
      <issn pub-type="epub">1873-4626</issn>
      <publisher>
        <publisher-name>Springer-Verlag</publisher-name>
        <publisher-loc>New York</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">17436128</article-id>
      <article-id pub-id-type="pmc">1852393</article-id>
      <article-id pub-id-type="publisher-id">91</article-id>
      <article-id pub-id-type="doi">10.1007/s11605-007-0091-5</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>CD24 Expression is an Independent Prognostic Marker in Cholangiocarcinoma</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Agrawal</surname>
            <given-names>Shefali</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kuvshinoff</surname>
            <given-names>Boris W.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Khoury</surname>
            <given-names>Thaer</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Yu</surname>
            <given-names>Jihnhee</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Javle</surname>
            <given-names>Milind M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>LeVea</surname>
            <given-names>Charles</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Groth</surname>
            <given-names>Jeff</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Coignet</surname>
            <given-names>Lionel J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Gibbs</surname>
            <given-names>John F.</given-names>
          </name>
          <address>
            <email>john.gibbs@roswellpark.org</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department of Surgical Oncology, Roswell Park Cancer Institute, State University of New York, Elm and Carlton Streets, Buffalo, NY 14263 USA </aff>
        <aff id="Aff2"><label>2</label>Department of Pathology, Roswell Park Cancer Institute, State University of New York, Buffalo, NY USA </aff>
        <aff id="Aff3"><label>3</label>Department of Biostatistics, Roswell Park Cancer Institute, State University of New York, Buffalo, NY USA </aff>
        <aff id="Aff4"><label>4</label>Department of Medical Oncology, Roswell Park Cancer Institute, State University of New York, Buffalo, NY USA </aff>
        <aff id="Aff5"><label>5</label>Department of Cancer Genetics, Roswell Park Cancer Institute, State University of New York, Buffalo, NY USA </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>17</day>
        <month>2</month>
        <year>2007</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>4</month>
        <year>2007</year>
      </pub-date>
      <volume>11</volume>
      <issue>4</issue>
      <fpage>445</fpage>
      <lpage>451</lpage>
      <permissions>
        <copyright-statement>&#xA9; The Society for Surgery of the Alimentary Tract 2007</copyright-statement>
      </permissions>
      <abstract>
        <p>CD24 has been described as an adverse prognostic marker in several malignancies. This study evaluates CD24 expression in cholangiocarcinoma and correlates the findings with clinicopathologic data and patient survival. Between 1996 and 2002, 22 consecutive patients with cholangiocarcinoma were treated at our institution. Demographic data, SEER stage, pathologic data, treatment, expression of CD24, mitogen-activated protein kinase (MAPK), phosphorylated MAPK, and survival were analyzed. The majority of the tumors demonstrated CD24 (81.8%) and p-MAPK (87%) expression. A negative association was noted between the expression of CD24 and p-MAPK. Median survival for patients with low expression of CD24 was 36&#xA0;months and high expression was 8&#xA0;months. Median survival for patients who received chemotherapy with low CD24 expression was 163&#xA0;months, and for seven patients with high CD24 expression, it was 17&#xA0;months (<italic>p</italic>&#x2009;=&#x2009;0.04). With the addition of radiation therapy, median survival for patients with low expression of CD24 was 52&#xA0;months and high expression was 17&#xA0;months (<italic>p</italic>&#x2009;=&#x2009;0.08). On multivariate analysis, the use of chemotherapy (<italic>p</italic>&#x2009;=&#x2009;0.0014, hazard ratio 0.069) and the CD24 overexpression (<italic>p</italic>&#x2009;=&#x2009;0.02, hazard ratio 7.528) were predictive of survival. CD24 is commonly expressed in cholangiocarcinoma, and overexpression is predictive of poor survival and possibly of lack of response to chemotherapy and radiation therapy. These findings may improve selection of patients for the appropriate treatment modality and the development of CD24-targeted therapy.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>CD24 expression</kwd>
        <kwd>Cholangiocarcinoma</kwd>
        <kwd>Survival</kwd>
      </kwd-group>
      <custom-meta-wrap>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Society for Surgery of the Alimentary Tract 2007</meta-value>
        </custom-meta>
      </custom-meta-wrap>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>Malignancies of the biliary tract are uncommon in the Western world. Two-thirds arise in the gallbladder and the remainder in the biliary tree or periampullary region. Cholangiocarcinoma or bile duct cancer is a rare but lethal malignancy with an incidence of 1&#x2013;2 cases per 100,000 patients in the United States.<xref ref-type="bibr" rid="CR1">1</xref> Clinicopathologic factors predictive of survival include curative resection, tumor stage and grade, serum bilirubin level &lt;10&#xA0;mg/dl, low CA19-9 level, hepatitis viral infection,<xref ref-type="bibr" rid="CR2">2</xref>&#x2013;<xref ref-type="bibr" rid="CR4">4</xref> lymphovascular or portal vein invasion,<xref ref-type="bibr" rid="CR5">5</xref> intrahepatic satellite lesions, inraductal papillary compvonent, tumor angiogenesis,<xref ref-type="bibr" rid="CR6">6</xref> and DNA ploidy.<xref ref-type="bibr" rid="CR7">7</xref> Reports of molecular markers predictive of survival in cholangiocarcinoma include cluster of differentiation CD24,<xref ref-type="bibr" rid="CR8">8</xref> MMP-2, TIMP-2,<xref ref-type="bibr" rid="CR9">9</xref> cholinesterase level,<xref ref-type="bibr" rid="CR10">10</xref> MUC-4,<xref ref-type="bibr" rid="CR11">11</xref> cyclin D1,<xref ref-type="bibr" rid="CR12">12</xref> VEGF-C,<xref ref-type="bibr" rid="CR13">13</xref> p27,<xref ref-type="bibr" rid="CR14">14</xref> p53, and p73.<xref ref-type="bibr" rid="CR15">15</xref></p>
      <p>Recently, CD24 has been described in a wide variety of malignancies and shown to be a prognostic marker in several solid tumors including colorectal, stomach, lung, prostate, ovarian, and breast.<xref ref-type="bibr" rid="CR16">16</xref>&#x2013;<xref ref-type="bibr" rid="CR21">21</xref> CD24 is a small, heavily glycosylated, mucin-like, cell-surface protein expressed in developing cells including pre-B cells, keratinocytes, and renal tubular epithelium.<xref ref-type="bibr" rid="CR22">22</xref>&#x2013;<xref ref-type="bibr" rid="CR24">24</xref> It functions as an alternative ligand of P-selectin, an adhesion receptor expressed on activated endothelial cells and platelets which can enhance the metastatic potential of CD24-expressing tumor cells.<xref ref-type="bibr" rid="CR25">25</xref>&#x2013;<xref ref-type="bibr" rid="CR28">28</xref> CD24 has apoptotic activity, and its cross-linking induces the sustained activation of p38 MAPK (mitogen-activated protein kinases)&#x2014;the magnitude of which may determine the survival or death of pre-B cells.<xref ref-type="bibr" rid="CR29">29</xref> An improved understanding of the molecular pathways involved in the pathogenesis and progression of cholangiocarcinoma will contribute to the development of targeted therapy.</p>
      <p>This study correlates CD24 and MAPK expression with patient survival in cholangiocarcinoma with the objective of identifying a subset of patients who may benefit from targeted molecular therapy.</p>
    </sec>
    <sec id="Sec2" sec-type="methods">
      <title>Patients and Methods</title>
      <sec id="Sec3">
        <title>Clinical Data</title>
        <p>After obtaining approval of the Institutional Review Board, a review of the tumor registry at Roswell Park Cancer Institute identified 31 consecutive patients with histologically proven cholangiocarcinoma between 1996 and 2002. Twenty-two patients had adequate tissue for further histopathologic studies and constitute the basis of this study. Medical records of these patients were reviewed for demographic data including age; gender; surveillance, epidemiology, and end results (SEER) stage at presentation; treatment; and survival from the time of diagnosis.</p>
      </sec>
      <sec id="Sec4">
        <title>Immunohistochemical Staining</title>
        <p>For most of the patients, diagnosis was established by examination of conventional hematoxylin and eosin (H&amp;E)-stained slides and, in the remainder diagnosis, was confirmed with ancillary techniques including immunohistochemistry and special histochemistry with mucin and PAS stains. Uniform tissue fixation techniques were used for all patients. For each patient, a representative block containing adequate neoplastic and nonneoplastic tissue was selected. Five-micrometer tissue sections from these blocks were placed on charged slides and dried in a 60&#xB0;C oven for 1&#xA0;h. Upon return to room temperature, the slides were deparaffinized in three changes of xylene and rehydrated using graded alcohols. Endogenous peroxidase was quenched with 3% aqueous H<sub>2</sub>O<sub>2</sub> for 15&#xA0;min and washed with phosphate buffered saline with 0.05% Tween-20 (PBS/T). CD24 primary antibody was obtained from BD Biosciences (clone ML5) and used with the recommended incubation time and antigen retrieval procedures. The primary antibody used for MAPK was obtained from Cell Signaling and for phosphorylated/activated MAPK from Santa Cruz. After a PBS/T wash, 0.03% casein (in PBS/T) was used as a block for 30&#xA0;min followed by the application of the primary antibody to the slides for an hour or overnight. Another PBS/T wash was followed by exposure to the biotinylated secondary antibody for 30&#xA0;min. A third PBS/T wash was followed by exposure to the streptavidin&#x2013;peroxidase complex for 30&#xA0;min. A PBS/T wash was followed by the application of the chromogen DAB (DAKO, Carpinteria CA, USA) for 5&#xA0;min. The slides were then counterstained with hematoxylin, rinsed with water, dehydrated, and cleared, and a coverslip was placed. The use of biomarkers, related controls, and interpretation of results using the Histoscore system for quantification of results have been described previously by our group.<xref ref-type="bibr" rid="CR30">30</xref> Histoscore was defined as the product of the percentage of positive cells and the intensity of stain. The grade of positive staining depended upon the intensity of staining (0: no staining, 1: weak, 2: moderate, and 3: strong staining) and the percentage of cells stained. The final score was calculated as a sum of each stain intensity multiplied by the percentage of stained cells in the area of interest. For example: if tumor showed 50% weak, 30% moderate, and 20% strong staining, the score assigned was <inline-formula id="IEq1"><!-- Alternate image not processed: 11605_2007_91_Article_IEq1.gif --><tex-math id="M1">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$ {\left( {50 \times 1} \right)} + {\left( {30 \times 2} \right)} + {\left( {20 \times 3} \right)} = 170 $$\end{document}</tex-math></inline-formula>.</p>
      </sec>
      <sec id="Sec5">
        <title>Histological Grading</title>
        <p>The cholangiocarcinoma tissue specimens were also stained by routine H&amp;E stains. The specimens were graded based on the degree of tumor differentiation using the World Health Organization (WHO) system.</p>
      </sec>
      <sec id="Sec6">
        <title>Statistical Analysis</title>
        <p>Association between biomarker expressions in tumor tissue was investigated using the Kendall&#x2019;s tau. Biomarker expressions were classified as high and low based on whether their scores were above or below the median value, and survival between low and high expressions was compared using the log-rank test. The Kaplan&#x2013;Meier method was also used to estimate the survival curves and median survival. The Cox&#x2019;s proportional hazards survival analysis was used in the multivariate analysis of survival data to explain the effect of biomarker expressions together with other diagnostic parameters. Patient demographics including age, tumor grade, SEER stage, and treatment received were considered as possible parameters for explanatory variables in the model. All statistical tests were two-sided with statistical significance level at 5%.</p>
      </sec>
    </sec>
    <sec id="Sec7" sec-type="results">
      <title>Results</title>
      <sec id="Sec8">
        <title>Patient Characteristics</title>
        <p>Of the 22 patients included in the study, 7 were males and 15 females. The median age was 66.5&#xA0;years (range: 35&#x2013;77). SEER staging was local in 1 (4.6%), regional in 14 (63.6%), and distant in 7 (31.8%) patients. Differentiation of the tumor was classified as grade 1 in 3 (13.6%), grade 2 in 9 (40.9%), and grade 3 in 10 (45.5%) patients according to the WHO classification. Treatment for cholangiocarcinoma included surgery only (<italic>n</italic>&#x2009;=&#x2009;8), surgery and chemotherapy (<italic>n</italic>&#x2009;=&#x2009;5), surgery and radiation (<italic>n</italic>&#x2009;=&#x2009;1), chemotherapy only (<italic>n</italic>&#x2009;=&#x2009;2), and all three treatment modalities (<italic>n</italic>&#x2009;=&#x2009;5), and one patient did not receive any treatment.</p>
      </sec>
      <sec id="Sec9">
        <title>Immunohistochemical Staining</title>
        <p>Normal bile duct staining was used to set the score intensity. Most of the bile ducts were negative. Occasionally, they demonstrated weak focal and incomplete staining as seen in Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>. The cholangiocarcinoma cells were scored as 1+ when they demonstrated weak expression of CD24, 2+ for moderate expression, and 3+ for strong expression of CD24. Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref> depicts cholangiocarcinoma positive for CD24 expression adjacent to normal biliary epithelium. The majority of the tumors demonstrated CD24 (81.8%) and p-MAPK (87%) expression. Immunohistochemical staining for these proteins was higher in malignant tissue in comparison to normal biliary epithelium. The pattern of staining was usually a combination of cytoplasmic and apical, and few specimens demonstrated the apical pattern only.
<fig id="Fig1"><label>Figure&#xA0;1</label><caption><p>Moderately differentiated cholangiocarcinoma with overexpression of CD24. Normal bile duct (<italic>right upper corner</italic>) demonstrated weak apical staining, whereas neoplastic cells had strong apical and cytoplasmic staining (20&#xD7;).</p></caption><graphic position="anchor" xlink:href="11605_2007_91_Fig1_HTML" id="MO1"/></fig></p>
      </sec>
      <sec id="Sec10">
        <title>Relationship Between Biomarkers</title>
        <p>A negative association was suggested between the expression of CD24 and phosphorylated/activated p-MAPK (Kendall&#x2019;s <italic>&#x3C4;</italic>&#x2009;=&#x2009;&#x2212;0.32408, <italic>p</italic>&#x2009;=&#x2009;0.0501).</p>
      </sec>
      <sec id="Sec11">
        <title>Survival</title>
        <p>Median survival was 36&#xA0;months for nine patients with low expression of CD24 and 8&#xA0;months for 13 patients with high expression of CD24 as shown in Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>. The median survival for five patients who received chemotherapy with low CD24 expression was 163&#xA0;months, and for seven patients with high CD24 expression, it was 17&#xA0;months (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>, <italic>p</italic>&#x2009;=&#x2009;0.04). Median survival for four patients treated with radiation in the presence of low CD24 expression was 52&#xA0;months, and it was 17&#xA0;months for two patients with overexpression of CD24 (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>, <italic>p</italic>&#x2009;=&#x2009;0.08). Overexpression of CD24 continued to affect survival adversely despite the overall improvement noted with the addition of radiation therapy. Multivariate analysis using the Cox&#x2019;s proportional hazards survival analysis demonstrated that overexpression of CD24 (<italic>p</italic>&#x2009;=&#x2009;0.02, hazard ratio 7.528) and use of chemotherapy (<italic>p</italic>&#x2009;=&#x2009;0.0014, hazard ratio 0.069) were predictive of survival (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). There was no significant association noted between survival and patient&#x2019;s age, sex, SEER stage, grade of the tumor, surgery, radiation therapy, or expression of MAPK.
<fig id="Fig2"><label>Figure&#xA0;2</label><caption><p>Kaplan&#x2013;Meier survival curve for patients of cholangiocarcinoma with low and high levels of CD24 expression (<italic>n</italic>&#x2009;=&#x2009;22). <italic>p</italic>&#x2009;=&#x2009;0.02. Low CD24 (&#x2013;&#x2013;&#x2013;&#x2013;&#x2013;&#x2013;&#x2013;), high CD24 (- - - - - - - - - - - -).</p></caption><graphic position="anchor" xlink:href="11605_2007_91_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Figure&#xA0;3</label><caption><p>Kaplan&#x2013;Meier survival curve for patients who received chemotherapy with low and high levels of CD24 expression (<italic>n</italic>&#x2009;=&#x2009;12). <italic>p</italic>&#x2009;=&#x2009;0.04. Low CD24 (&#x2013;&#x2013;&#x2013;&#x2013;&#x2013;&#x2013;&#x2013;), high CD24 (&#x2013; - &#x2013; - &#x2013; - &#x2013;).</p></caption><graphic position="anchor" xlink:href="11605_2007_91_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Figure&#xA0;4</label><caption><p>Kaplan&#x2013;Meier survival curve for patients who received radiation therapy with low and high levels of CD24 expression (<italic>n</italic>&#x2009;=&#x2009;6). <italic>p</italic>&#x2009;=&#x2009;0.08. Low CD24 (&#x2013;&#x2013;&#x2013;&#x2013;&#x2013;&#x2013;&#x2013;), high CD24 (&#x2013; - &#x2013; - &#x2013; - &#x2013;).</p></caption><graphic position="anchor" xlink:href="11605_2007_91_Fig4_HTML" id="MO4"/></fig><table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Prognostic Variables for Survival in 22 Patients with Cholangiocarcinoma</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th><italic>n</italic></th><th>Median survival (months)</th><th>Survival (<italic>p</italic> value)</th><th>Multivariate analysis (<italic>p</italic> value)</th></tr></thead><tbody><tr><td colspan="5">Age</td></tr><tr><td>&lt;68</td><td>11</td><td>17 (8&#x2013;36)</td><td rowspan="2">0.60</td><td/></tr><tr><td>&gt;68</td><td>11</td><td>11 (5&#x2013;52)</td><td/></tr><tr><td colspan="5">Gender</td></tr><tr><td>Male</td><td>7</td><td>12 (8&#x2013;163)</td><td rowspan="2">0.52</td><td/></tr><tr><td>Female</td><td>15</td><td>17 (6&#x2013;52)</td><td/></tr><tr><td colspan="5">Grade</td></tr><tr><td>1, 2</td><td>12</td><td>15 (6&#x2013;52)</td><td rowspan="2">0.99</td><td/></tr><tr><td>3</td><td>10</td><td>11 (8&#x2013;*)</td><td/></tr><tr><td colspan="5">SEER stage</td></tr><tr><td>1, 2</td><td>15</td><td>11 (6&#x2013;52)</td><td rowspan="2">0.48</td><td/></tr><tr><td>3</td><td>7</td><td>28 (6&#x2013;163)</td><td/></tr><tr><td colspan="5">Chemotherapy</td></tr><tr><td>No</td><td>10</td><td>6 (4&#x2013;13)</td><td rowspan="2">0.0005</td><td rowspan="2">0.0014</td></tr><tr><td>Yes</td><td>12</td><td>52 (17&#x2013;163)</td></tr><tr><td colspan="5">Radiation</td></tr><tr><td>No</td><td>16</td><td>8 (6&#x2013;28)</td><td rowspan="2">0.12</td><td/></tr><tr><td>Yes</td><td>6</td><td>44 (17&#x2013;*)</td><td/></tr><tr><td colspan="5">Surgery</td></tr><tr><td>No</td><td>3</td><td>8 (0&#x2013;28)</td><td rowspan="2">0.17</td><td/></tr><tr><td>Yes</td><td>19</td><td>17 (7&#x2013;52)</td><td/></tr><tr><td colspan="5">MAPK</td></tr><tr><td>Low</td><td>10</td><td>17 (8&#x2013;36)</td><td rowspan="2">0.68</td><td/></tr><tr><td>High</td><td>11</td><td>28 (5&#x2013;163)</td><td/></tr><tr><td colspan="5">P-MAPK</td></tr><tr><td>Low</td><td>10</td><td>13 (8&#x2013;52)</td><td rowspan="2">0.34</td><td/></tr><tr><td>High</td><td>11</td><td>36 (4&#x2013;163)</td><td/></tr><tr><td colspan="5">CD24</td></tr><tr><td>&lt;120</td><td>9</td><td>36 (13&#x2013;163)</td><td rowspan="2">0.10</td><td rowspan="2">0.02</td></tr><tr><td>&gt;120</td><td>13</td><td>8 (6&#x2013;28)</td></tr></tbody></table><table-wrap-foot><p>*The estimate was not provided because the upper limit of the survival curve had not reached a 50% failure rate.</p><p>CD denotes cluster of differentiation.</p><p>p-MAPK denotes phosphorylated form of mitogen-activated protein kinase.</p></table-wrap-foot></table-wrap></p>
      </sec>
    </sec>
    <sec id="Sec12" sec-type="discussion">
      <title>Discussion</title>
      <p>The physiologic function of CD24 is incompletely understood but it has been shown to increase tumor proliferation, cell adhesion, motility, invasion, and apoptosis.<xref ref-type="bibr" rid="CR22">22</xref>&#x2013;<xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR31">31</xref> Selectins are cell adhesion molecules involved in the rolling adhesion of leukocytes to endothelial cells and platelets under the shear forces of circulation, and P-selectin expressed by thrombin-activated platelets and endothelial cells is a major ligand for CD24 on carcinoma cells.<xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR27">27</xref> This suggests that CD24-expressing tumor cells can disseminate more readily due to their capacity to form thrombi with activated platelets or to adhere to endothelial cells. Friederichs et al.<xref ref-type="bibr" rid="CR28">28</xref> have demonstrated that the carbohydrate sialylLex abundantly expressed on human cancers is essential for CD24-mediated rolling of tumor cells on P-selectin, and in its absence, human adenocarcinoma cells failed to arrest and colonize the lungs. CD24, a metastasis-associated protein, has been recently identified as a downstream target of Ral signaling.<xref ref-type="bibr" rid="CR32">32</xref> Ral GTPases are important mediators of transformation, tumorigenesis, and cancer progression. Microarray by immunohistochemistry of a human bladder cancer identified CD24 as a novel Ral-regulated target and a prognostic biological marker.</p>
      <p>In this study, 81.8% of patients with cholangiocarcinoma expressed CD24. Median survival for patients with overexpression of CD24 was significantly shorter, and the addition of chemotherapy improved survival. A negative association was noted between the expression of CD24 and p-MAPK. The use of chemotherapy in patients with low expression of CD24 was associated with a median survival of 163&#xA0;months compared to 17&#xA0;months in patients with a high CD24 expression (<italic>p</italic>&#x2009;=&#x2009;0.04). The use of radiation therapy in patients with low expression of CD24 was also associated with an improved survival than with overexpression of CD24 although the data did not attain statistical significance possibly due to the small number of patients in this series.</p>
      <p>It has been reported by Taguchi et al.<xref ref-type="bibr" rid="CR29">29</xref> that the cross-linking of CD24 induces apoptosis in Burkitt&#x2019;s lymphoma enhanced by a B-cell antigen receptor (BCR)-mediated signal. They observed that simultaneous cross-linking of pre-BCR clearly inhibited CD24-mediated apoptosis in pre-B cells. CD24 cross-linking also induces the sustained activation of p38 MAPK, and whether pre-B cells survive or die may be determined by the magnitude of MAPK activation. Consistent with these observations, the present study suggests an inverse association between CD24 and p-MAPK, and eventual cellular proliferation or apoptosis might be a consequence of the dominant effect in a complex interplay of opposing influences.<xref ref-type="bibr" rid="CR33">33</xref></p>
      <p>Our data indicate that high expression of CD24 remains an adverse prognosticator despite the use of additional therapy. Chemotherapy and radiation were noted to provide maximal survival benefit to low expressors of CD24 although the data for the use of radiation was statistically insignificant probably due to the small number of patients in this study. Furthermore, correlation between CD24 expression and radiation sensitivity has been noted to vary with the cell type as in human small cell lung cancer, and radiation doses required to induce apoptosis of CD24-negative human ALL (acute lymphoblastic leukemia) cells were higher than those required for CD24-positive cells, suggesting that lack of CD24 surface antigen expression is associated with intrinsic radiation resistance.<xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref></p>
      <p>Hypoxia is a characteristic feature of tumor cells due to the sustained proliferation which progressively results in an acidic, nutrient-deprived, and hypoxic tumor microenvironment. Tumor oxygenation has been identified as an independent prognostic variable for locoregional control and overall survival following definitive irradiation for squamous cell carcinoma of the head, neck, and uterine cervix.<xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR37">37</xref> Recent reports have indicated decreased efficacy of chemotherapy under hypoxic conditions in several tumor types including pancreatic cancer and testicular tumors.<xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR39">39</xref> Because treatment failure was a consequence of hypoxia, the authors recommend novel treatment strategies aimed at improving tumor oxygenation or enhancing the treatment sensitivity of hypoxic tumor cells. Aimed at identifying potential oxygen-dependent markers in vascular endothelial cells for therapeutic intervention in tumor angiogenesis, Scheurer et al.<xref ref-type="bibr" rid="CR40">40</xref> performed a broad-range transcriptomic analysis of selected extracellular matrix protein gene expression levels in human umbilical cord vein endothelial cells exposed in vitro to hypoxia for different time periods. They noted several genes transcriptionally upregulated including CD24 at late times of exposure to hypoxia, indicating that it was a useful marker of hypoxic activation in vascular endothelial cells. In the present series, low expressors of CD24 demonstrated greater survival benefit from chemotherapy and radiation than the high expressors, suggesting that its expression may be a marker for tumor hypoxia and response to therapy. This finding that shows that patients with low expression of CD24 may benefit from chemotherapy or radiation is of importance because it has been previously reported that adjuvant or palliative radiation had no effect on survival in patients with cholangiocarcinoma.<xref ref-type="bibr" rid="CR41">41</xref> However, the small number of patients in the present series limits interpretation of data suggesting that CD24 overexpression may be predictive of lack of response to radiation or chemotherapy.</p>
      <p>CD24 has been shown to be a prognostic marker for shortened survival and disease progression in several malignancies including colorectal, stomach, lung, prostate, ovarian, and breast cancers.<xref ref-type="bibr" rid="CR16">16</xref>&#x2013;<xref ref-type="bibr" rid="CR21">21</xref> Weichert et al. report that in colorectal cancer, only the subset of patients with exceptionally strong cytoplasmic CD24 staining comprising 10% of their study group demonstrated a markedly shortened mean survival of 31.5&#xA0;months compared to 67.5&#xA0;months for the remaining patients.<xref ref-type="bibr" rid="CR16">16</xref> They also reported that cytoplasmic CD24 staining pattern is prognostically more significant than the membranous pattern&#x2014;the biological significance of which was unclear. Su et al. noted a 51% expression of CD24 by immunohistochemistry in intrahepatic cholangiocarcinoma as compared to the 81.8% in the present series. They reported CD24 expression and tumor stage as independently predictive of survival on multivariate analysis and suggested membrane-bound CD24 protein as a potential target for immunotherapy.<xref ref-type="bibr" rid="CR8">8</xref></p>
      <p>In conclusion, overexpression of the molecular marker CD24 in cholangiocarcinoma is predictive of poor survival. CD24 overexpressors demonstrated a lack of response to chemotherapy and possibly radiation therapy although these observations were limited by the small sample size. Additional properties of tumor proliferation, invasion, metastasis, and apoptosis make CD24 a potent target for specifically directed molecular therapy and its overexpression a potential criterion in the selection of patients for the appropriate conventional treatment modality.</p>
    </sec>
  </body>
  <back>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Burke</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Jarnagin</surname>
              <given-names>WR</given-names>
            </name>
            <name>
              <surname>Hochwald</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Pisters</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Fong</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Blumgart</surname>
              <given-names>LH</given-names>
            </name>
          </person-group>
          <article-title>Hilar cholangiocarcinoma: patterns of spread, importance of hepatic resection for curative operation and a presurgical clinical staging system</article-title>
          <source>Ann Surg</source>
          <year>1998</year>
          <volume>228</volume>
          <fpage>385</fpage>
          <lpage>394</lpage>
          <pub-id pub-id-type="doi">10.1097/00000658-199809000-00011</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Burke EC, Jarnagin WR, Hochwald SN, Pisters PW, Fong Y, Blumgart LH. Hilar cholangiocarcinoma: patterns of spread, importance of hepatic resection for curative operation and a presurgical clinical staging system. Ann Surg 1998;228:385&#x2013;394. <pub-id pub-id-type="pmid">9742921</pub-id></citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nagorney</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Donohue</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Farnell</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Schleck</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Ilstrup</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>Outcomes after curative resections of cholangiocarcinoma</article-title>
          <source>Arch Surg</source>
          <year>1993</year>
          <volume>128</volume>
          <issue>8</issue>
          <fpage>871</fpage>
          <lpage>877</lpage>
        </citation>
        <citation citation-type="display-unstructured">Nagorney DM, Donohue JH, Farnell MB, Schleck CD, Ilstrup DM. Outcomes after curative resections of cholangiocarcinoma. Arch Surg 1993;128(8):871&#x2013;877. <pub-id pub-id-type="pmid">8393652</pub-id></citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klempnauer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rideer</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Wasielewski</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Werner</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Weimann</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pichmayr</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors</article-title>
          <source>J Clin Oncol</source>
          <year>1997</year>
          <volume>15</volume>
          <issue>3</issue>
          <fpage>947</fpage>
          <lpage>954</lpage>
        </citation>
        <citation citation-type="display-unstructured">Klempnauer J, Rideer GJ, von Wasielewski R, Werner M, Weimann A, Pichmayr R. Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. J Clin Oncol 1997;15(3):947&#x2013;954. <pub-id pub-id-type="pmid">9060532</pub-id></citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abdel Wahab</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fathy</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Elghwalby</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Sultan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Elebidy</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Abdalla</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Elshobary</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mostafa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Foad</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kandeel</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Abdel Raouf</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Salah</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Abu Zeid</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Abu Elenein</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gad Elhak</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>ElFiky</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ezzat</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Resectability and prognostic factors after resection of hilar cholangiocarcinoma</article-title>
          <source>Hepatogastroenterology</source>
          <year>2006</year>
          <volume>53</volume>
          <issue>67</issue>
          <fpage>5</fpage>
          <lpage>10</lpage>
        </citation>
        <citation citation-type="display-unstructured">Abdel Wahab M, Fathy O, Elghwalby N, Sultan A, Elebidy E, Abdalla T, Elshobary M, Mostafa M, Foad A, Kandeel T, Abdel Raouf A, Salah T, Abu Zeid M, Abu Elenein A, Gad Elhak N, ElFiky A, Ezzat F. Resectability and prognostic factors after resection of hilar cholangiocarcinoma. Hepatogastroenterology 2006;53(67):5&#x2013;10. <pub-id pub-id-type="pmid">16506367</pub-id></citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ebata</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nagino</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kamiya</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Uesaka</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nagasaka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nimura</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases</article-title>
          <source>Ann Surg</source>
          <year>2003</year>
          <volume>238</volume>
          <issue>5</issue>
          <fpage>720</fpage>
          <lpage>727</lpage>
          <pub-id pub-id-type="doi">10.1097/01.sla.0000094437.68038.a3</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Ebata T, Nagino M, Kamiya J, Uesaka K, Nagasaka T, Nimura Y. Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases. Ann Surg 2003;238(5):720&#x2013;727. <pub-id pub-id-type="pmid">14578735</pub-id></citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shirabe</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Shimada</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tsujita</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prognostic factors in node-negative intrahepatic cholangiocarcinoma with special reference to angiogenesis</article-title>
          <source>Am J Surg</source>
          <year>2004</year>
          <volume>187</volume>
          <issue>4</issue>
          <fpage>538</fpage>
          <lpage>542</lpage>
          <pub-id pub-id-type="doi">10.1016/j.amjsurg.2003.12.044</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Shirabe K, Shimada M, Tsujita E et al. Prognostic factors in node-negative intrahepatic cholangiocarcinoma with special reference to angiogenesis. Am J Surg 2004;187(4):538&#x2013;542. <pub-id pub-id-type="pmid">15041507</pub-id></citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abou-Rebyeh</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Al-Abadi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Jonas</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rotter</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Bechstein</surname>
              <given-names>WO</given-names>
            </name>
            <name>
              <surname>Neuhaus</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>DNA analysis of cholangiocarcinoma cells: prognostic and clinical importance</article-title>
          <source>Cancer Detect Prev</source>
          <year>2002</year>
          <volume>26</volume>
          <issue>4</issue>
          <fpage>313</fpage>
          <lpage>319</lpage>
          <pub-id pub-id-type="doi">10.1016/S0361-090X(02)00057-0</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Abou-Rebyeh H, Al-Abadi H, Jonas S, Rotter I, Bechstein WO, Neuhaus P. DNA analysis of cholangiocarcinoma cells: prognostic and clinical importance. Cancer Detect Prev 2002;26(4):313&#x2013;319. <pub-id pub-id-type="pmid">12430636</pub-id></citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Su</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Hsu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kao</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Jeng</surname>
              <given-names>YM</given-names>
            </name>
          </person-group>
          <article-title>CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma</article-title>
          <source>Cancer Lett</source>
          <year>2006</year>
          <volume>235</volume>
          <issue>1</issue>
          <fpage>34</fpage>
          <lpage>349</lpage>
          <pub-id pub-id-type="doi">10.1016/j.canlet.2005.03.059</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Su MC, Hsu C, Kao HL, Jeng YM. CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma. Cancer Lett 2006;235(1):34&#x2013;349. <pub-id pub-id-type="pmid">16125303</pub-id></citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xiao</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>NX</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>ZQ</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>YL</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>WL</given-names>
            </name>
          </person-group>
          <article-title>The ratio of MMP-2 to TIMP-2 in hilar cholangiocarcinoma: a semi-quantitative study</article-title>
          <source>Hepatobiliary Pancreat Dis Int</source>
          <year>2004</year>
          <volume>3</volume>
          <issue>4</issue>
          <fpage>599</fpage>
          <lpage>602</lpage>
        </citation>
        <citation citation-type="display-unstructured">Xiao M, Zhou NX, Huang ZQ, Lu YL, Chen LH, Wang DJ, Chang WL. The ratio of MMP-2 to TIMP-2 in hilar cholangiocarcinoma: a semi-quantitative study. Hepatobiliary Pancreat Dis Int 2004;3(4):599&#x2013;602. <pub-id pub-id-type="pmid">15567754</pub-id></citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hamamoto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Niino</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ishiyama</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hosoya</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Impact of pretreatment cholinesterase level on survival of inoperable intrahepatic or hepatic&#x2013;hilar carcinomas treated with three-dimensional conformal radiotherapy</article-title>
          <source>Radiat Med</source>
          <year>2004</year>
          <volume>22</volume>
          <issue>5</issue>
          <fpage>316</fpage>
          <lpage>323</lpage>
        </citation>
        <citation citation-type="display-unstructured">Hamamoto Y, Niino K, Ishiyama H, Hosoya T. Impact of pretreatment cholinesterase level on survival of inoperable intrahepatic or hepatic&#x2013;hilar carcinomas treated with three-dimensional conformal radiotherapy. Radiat Med 2004;22(5):316&#x2013;323. <pub-id pub-id-type="pmid">15553012</pub-id></citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shibahara</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tamada</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Higashi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Goto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Batra</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Imai</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yonezawa</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type</article-title>
          <source>Hepatology</source>
          <year>2004</year>
          <volume>39</volume>
          <issue>1</issue>
          <fpage>220</fpage>
          <lpage>229</lpage>
          <pub-id pub-id-type="doi">10.1002/hep.20031</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Shibahara H, Tamada S, Higashi M, Goto M, Batra SK, Imai K, Yonezawa S. MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology 2004;39(1):220&#x2013;229. <pub-id pub-id-type="pmid">14752841</pub-id></citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sugimachi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Aishima</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Taguchi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shimada</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kajiyama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sugimachi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tsuneyoshi</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>The role of overexpression and gene amplification of cyclin D1 in intrahepatic cholangiocarcinoma</article-title>
          <source>J Hepatol</source>
          <year>2001</year>
          <volume>35</volume>
          <issue>1</issue>
          <fpage>74</fpage>
          <lpage>79</lpage>
          <pub-id pub-id-type="doi">10.1016/S0168-8278(01)00079-4</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Sugimachi K, Aishima S, Taguchi K, Tanaka S, Shimada M, Kajiyama K, Sugimachi K, Tsuneyoshi M. The role of overexpression and gene amplification of cyclin D1 in intrahepatic cholangiocarcinoma. J Hepatol 2001;35(1):74&#x2013;79. <pub-id pub-id-type="pmid">11495045</pub-id></citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Park</surname>
              <given-names>BK</given-names>
            </name>
            <name>
              <surname>Paik</surname>
              <given-names>YH</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>KH</given-names>
            </name>
            <name>
              <surname>Bang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>YN</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>SY</given-names>
            </name>
          </person-group>
          <article-title>The clinicopathologic significance of the expression of vascular endothelial growth factor-C in intrahepatic cholangiocarcinoma</article-title>
          <source>Am J Clin Oncol</source>
          <year>2006</year>
          <volume>29</volume>
          <issue>2</issue>
          <fpage>138</fpage>
          <lpage>142</lpage>
          <pub-id pub-id-type="doi">10.1097/01.coc.0000204402.29830.08</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Park BK, Paik YH, Park JY, Park KH, Bang S, Park SW, Chung JB, Park YN, Song SY. The clinicopathologic significance of the expression of vascular endothelial growth factor-C in intrahepatic cholangiocarcinoma. Am J Clin Oncol 2006;29(2):138&#x2013;142. <pub-id pub-id-type="pmid">16601431</pub-id></citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fiorentino</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Altimari</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>D&#x2019;Errico</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gabusi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Chieco</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Masetti</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Grigioni</surname>
              <given-names>WF</given-names>
            </name>
          </person-group>
          <article-title>Low p27 expression is an independent predictor of survival for patients with either hilar or peripheral intrahepatic cholangiocarcinoma</article-title>
          <source>Clin Cancer Res</source>
          <year>2001</year>
          <volume>7</volume>
          <issue>12</issue>
          <fpage>3994</fpage>
          <lpage>3999</lpage>
        </citation>
        <citation citation-type="display-unstructured">Fiorentino M, Altimari A, D&#x2019;Errico A, Gabusi E, Chieco P, Masetti M, Grigioni WF. Low p27 expression is an independent predictor of survival for patients with either hilar or peripheral intrahepatic cholangiocarcinoma. Clin Cancer Res 2001;7(12):3994&#x2013;3999. <pub-id pub-id-type="pmid">11751492</pub-id></citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tannapfel</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Engeland</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Weinans</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Katalinic</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hauss</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Mossner</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wittekind</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver</article-title>
          <source>Br J Cancer</source>
          <year>1999</year>
          <volume>80</volume>
          <issue>7</issue>
          <fpage>1069</fpage>
          <lpage>1074</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.bjc.6690465</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Tannapfel A, Engeland K, Weinans L, Katalinic A, Hauss J, Mossner J, Wittekind C. Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver. Br J Cancer 1999;80(7):1069&#x2013;1074. <pub-id pub-id-type="pmid">10362118</pub-id></citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weichert</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Denkert</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Burkhardt</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gansukh</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Bellach</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Altevogt</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Dietel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kristansen</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival</article-title>
          <source>Clin Cancer Res</source>
          <year>2005</year>
          <volume>11</volume>
          <issue>18</issue>
          <fpage>6572</fpage>
          <lpage>6581</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-0606</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Weichert W, Denkert C, Burkhardt M, Gansukh T, Bellach J, Altevogt P, Dietel M, Kristansen G. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res 2005;11(18):6572&#x2013;6581. </citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lim</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Oh</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
          <article-title>The role of CD24 in various human epithelial neoplasias</article-title>
          <source>Pathol Res Pract</source>
          <year>2005</year>
          <volume>201</volume>
          <issue>7</issue>
          <fpage>479</fpage>
          <lpage>486</lpage>
          <pub-id pub-id-type="doi">10.1016/j.prp.2005.05.004</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Lim SC, Oh SH. The role of CD24 in various human epithelial neoplasias. Pathol Res Pract 2005;201(7):479&#x2013;486. <pub-id pub-id-type="pmid">16164042</pub-id></citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kristiansen</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schluns</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yongwei</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Denkert</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Dietel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Petersen</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients</article-title>
          <source>Brit J Cancer</source>
          <year>2003</year>
          <volume>88</volume>
          <fpage>231</fpage>
          <lpage>236</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.bjc.6600702</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kristiansen G, Schluns K, Yongwei Y, Denkert C, Dietel M, Petersen I. CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Brit J Cancer 2003;88:231&#x2013;236. <pub-id pub-id-type="pmid">12610508</pub-id></citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kristiansen</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pilarsky</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pervan</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sturzebecher</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Stephan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Loening</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rosenthal</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dietel</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer</article-title>
          <source>Prostate</source>
          <year>2004</year>
          <volume>58</volume>
          <fpage>183</fpage>
          <lpage>192</lpage>
          <pub-id pub-id-type="doi">10.1002/pros.10324</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kristiansen G, Pilarsky C, Pervan J, Sturzebecher B, Stephan C, Jung K, Loening S, Rosenthal A, Dietel M. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 2004;58:183&#x2013;192. <pub-id pub-id-type="pmid">14716744</pub-id></citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kristiansen</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Denkert</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schluns</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Dahl</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Pilarsky</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hauptmann</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival</article-title>
          <source>Am J Pathol</source>
          <year>2002</year>
          <volume>161</volume>
          <issue>4</issue>
          <fpage>1215</fpage>
          <lpage>1221</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kristiansen G, Denkert C, Schluns K, Dahl E, Pilarsky C, Hauptmann S. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 2002;161(4):1215&#x2013;1221. <pub-id pub-id-type="pmid">12368195</pub-id></citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kristiansen</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Winzer</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Mayordomo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bellach</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Schluns</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Denkert</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Dahl</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Pilarsky</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Altevogt</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Guski</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Dietel</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>CD24 expression is a new prognostic marker in breast cancer</article-title>
          <source>Clin Cancer Res</source>
          <year>2003</year>
          <volume>9</volume>
          <fpage>4906</fpage>
          <lpage>4913</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kristiansen G, Winzer KJ, Mayordomo E, Bellach J, Schluns K, Denkert C, Dahl E, Pilarsky C, Altevogt P, Guski H, Dietel M. CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 2003;9:4906&#x2013;4913. <pub-id pub-id-type="pmid">14581365</pub-id></citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pirrucello</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>LeBien</surname>
              <given-names>TW</given-names>
            </name>
          </person-group>
          <article-title>The human B cell-association antigen CD24 is a single chain sialoglycoprotein</article-title>
          <source>J Immunol</source>
          <year>1986</year>
          <volume>136</volume>
          <fpage>3779</fpage>
          <lpage>3784</lpage>
        </citation>
        <citation citation-type="display-unstructured">Pirrucello SJ, LeBien TW. The human B cell-association antigen CD24 is a single chain sialoglycoprotein. J Immunol 1986;136:3779&#x2013;3784. <pub-id pub-id-type="pmid">2939133</pub-id></citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fischer</surname>
              <given-names>GF</given-names>
            </name>
            <name>
              <surname>Majdic</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Gadd</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Knapp</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Signal transduction in lymphocytic and myeloid cells via CD24, a new member of phosphoinositol-anchored membrane molecules</article-title>
          <source>J Immunol</source>
          <year>1990</year>
          <volume>144</volume>
          <fpage>638</fpage>
          <lpage>641</lpage>
        </citation>
        <citation citation-type="display-unstructured">Fischer GF, Majdic O, Gadd S, Knapp W. Signal transduction in lymphocytic and myeloid cells via CD24, a new member of phosphoinositol-anchored membrane molecules. J Immunol 1990;144:638&#x2013;641. <pub-id pub-id-type="pmid">2153173</pub-id></citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Akashi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Shirasawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hirokawa</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Gene expression of CD24 core polypeptide molecule in normal rat tissues and human tumor cell lines</article-title>
          <source>Virchows Arch</source>
          <year>1994</year>
          <volume>425</volume>
          <fpage>399</fpage>
          <lpage>406</lpage>
          <pub-id pub-id-type="doi">10.1007/BF00189578</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Akashi T, Shirasawa T, Hirokawa K. Gene expression of CD24 core polypeptide molecule in normal rat tissues and human tumor cell lines. Virchows Arch 1994;425:399&#x2013;406. <pub-id pub-id-type="pmid">7820302</pub-id></citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aigner</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ruppert</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hubbe</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sammar</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sthoeger</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Butcher</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Vestweber</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Altevogt</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Heat stable antigen (mouse CD24) supports myeloid cell binding to endothelial and platelet P-selectin</article-title>
          <source>Int Immunol</source>
          <year>1995</year>
          <volume>7</volume>
          <issue>10</issue>
          <fpage>1557</fpage>
          <lpage>1565</lpage>
          <pub-id pub-id-type="doi">10.1093/intimm/7.10.1557</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Aigner S, Ruppert M, Hubbe M, Sammar M, Sthoeger Z, Butcher EC, Vestweber D, Altevogt P. Heat stable antigen (mouse CD24) supports myeloid cell binding to endothelial and platelet P-selectin. Int Immunol 1995;7(10):1557&#x2013;1565. <pub-id pub-id-type="pmid">8562500</pub-id></citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aigner</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sthoeger</surname>
              <given-names>ZM</given-names>
            </name>
            <name>
              <surname>Fogel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Zarn</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ruppert</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zeller</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Vestweber</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Stahel</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sammar</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Altevogt</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>CD24 a mucin-type glycoprotein is a ligand for P-selectin on human tumor cells</article-title>
          <source>Blood</source>
          <year>1997</year>
          <volume>89</volume>
          <issue>9</issue>
          <fpage>3385</fpage>
          <lpage>3395</lpage>
        </citation>
        <citation citation-type="display-unstructured">Aigner S, Sthoeger ZM, Fogel M, Weber E, Zarn J, Ruppert M, Zeller Y, Vestweber D, Stahel R, Sammar M, Altevogt P. CD24 a mucin-type glycoprotein is a ligand for P-selectin on human tumor cells. Blood 1997;89(9):3385&#x2013;3395. <pub-id pub-id-type="pmid">9129046</pub-id></citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aigner</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ramos</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Hafezi-Moghadam</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lawrence</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Friederichs</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Altevogt</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ley</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>CD24 mediates rolling of breast carcinoma cells on P-selectin</article-title>
          <source>FASEB J</source>
          <year>1998</year>
          <volume>12</volume>
          <issue>12</issue>
          <fpage>1241</fpage>
          <lpage>1251</lpage>
        </citation>
        <citation citation-type="display-unstructured">Aigner S, Ramos CL, Hafezi-Moghadam A, Lawrence MB, Friederichs J, Altevogt P, Ley K. CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J 1998;12(12):1241&#x2013;1251. <pub-id pub-id-type="pmid">9737727</pub-id></citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Friederichs</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zeller</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hafezi-Moghadam</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Grone</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Ley</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Altevogt</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells</article-title>
          <source>Cancer Res</source>
          <year>2000</year>
          <volume>60</volume>
          <issue>23</issue>
          <fpage>6714</fpage>
          <lpage>6722</lpage>
        </citation>
        <citation citation-type="display-unstructured">Friederichs J, Zeller Y, Hafezi-Moghadam A, Grone HJ, Ley K, Altevogt P. The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells. Cancer Res 2000;60(23):6714&#x2013;6722. <pub-id pub-id-type="pmid">11118057</pub-id></citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taguchi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kiyokawa</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Mimori</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sekino</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nakajima</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Saito</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Katagiri</surname>
              <given-names>YU</given-names>
            </name>
            <name>
              <surname>Matsuo</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Matsuo</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Karasuyama</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fujimoto</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Pre-B cell antigen receptor-mediated signal inhibits CD24-induced apoptosis in human pre-B cells</article-title>
          <source>J Immunol</source>
          <year>2003</year>
          <volume>170</volume>
          <issue>1</issue>
          <fpage>252</fpage>
          <lpage>260</lpage>
        </citation>
        <citation citation-type="display-unstructured">Taguchi T, Kiyokawa N, Mimori K, Suzuki T, Sekino T, Nakajima H, Saito M, Katagiri YU, Matsuo N, Matsuo Y, Karasuyama H, Fujimoto J. Pre-B cell antigen receptor-mediated signal inhibits CD24-induced apoptosis in human pre-B cells. J Immunol 2003;170(1):252&#x2013;260. <pub-id pub-id-type="pmid">12496407</pub-id></citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Malik</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Brattain</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ghosh</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Troyer</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Prihoda</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bedolla</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kreisberg</surname>
              <given-names>JI</given-names>
            </name>
          </person-group>
          <article-title>Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer</article-title>
          <source>Clin Cancer Res</source>
          <year>2002</year>
          <volume>8</volume>
          <fpage>1168</fpage>
          <lpage>1171</lpage>
        </citation>
        <citation citation-type="display-unstructured">Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda R, Bedolla R, Kreisberg JI. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002;8:1168&#x2013;1171. <pub-id pub-id-type="pmid">11948129</pub-id></citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baumann</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Cremers</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kroese</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Orend</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Chiquet-Ehrismann</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Uede</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yaqita</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sleeman</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis</article-title>
          <source>Cancer Res</source>
          <year>2005</year>
          <volume>65</volume>
          <issue>23</issue>
          <fpage>10783</fpage>
          <lpage>10793</lpage>
          <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-0619</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Baumann P, Cremers N, Kroese F, Orend G, Chiquet-Ehrismann R, Uede T, Yaqita H, Sleeman JP. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res 2005;65(23):10783&#x2013;10793. <pub-id pub-id-type="pmid">16322224</pub-id></citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smith</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Oxford</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Nitz</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Conaway</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Frierson</surname>
              <given-names>HF</given-names>
            </name>
            <name>
              <surname>Hampton</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Theodorescu</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer</article-title>
          <source>Cancer Res</source>
          <year>2006</year>
          <volume>66</volume>
          <issue>4</issue>
          <fpage>1917</fpage>
          <lpage>1922</lpage>
          <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-3855</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Smith SC, Oxford G, Wu Z, Nitz MD, Conaway M, Frierson HF, Hampton G, Theodorescu D. The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res 2006;66(4):1917&#x2013;1922. <pub-id pub-id-type="pmid">16488989</pub-id></citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <citation citation-type="other">Javle MM, Yu J, Khoury T. AKT expression may predict favorable prognosis in cholangiocarcinoma. J Gastroenterol Hepatol 21:1744&#x2013;1751.</citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Uckun</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>CW</given-names>
            </name>
          </person-group>
          <article-title>Lack of CD24 antigen expression in B-lineage acute lymphoblastic leukemia is associated with intrinsic radiation resistance of primary clonogenic blasts</article-title>
          <source>Blood</source>
          <year>1993</year>
          <volume>81</volume>
          <issue>5</issue>
          <fpage>1323</fpage>
          <lpage>1332</lpage>
        </citation>
        <citation citation-type="display-unstructured">Uckun FM, Song CW. Lack of CD24 antigen expression in B-lineage acute lymphoblastic leukemia is associated with intrinsic radiation resistance of primary clonogenic blasts. Blood 1993;81(5):1323&#x2013;1332. <pub-id pub-id-type="pmid">8443393</pub-id></citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weber</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Schmitter</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Resch</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Zarn</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Waibel</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mabry</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Huquenin</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Stahel</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Radiation studies on B cell differentiation marker CD24/SCLC Cluster-4 antigen expressing and non-expressing lung cancer cell lines and mouse fibroblasts</article-title>
          <source>Int J Radiat Biol</source>
          <year>1995</year>
          <volume>68</volume>
          <issue>2</issue>
          <fpage>205</fpage>
          <lpage>213</lpage>
        </citation>
        <citation citation-type="display-unstructured">Weber E, Schmitter D, Resch H, Zarn JA, Waibel R, Mabry M, Huquenin P, Stahel RA. Radiation studies on B cell differentiation marker CD24/SCLC Cluster-4 antigen expressing and non-expressing lung cancer cell lines and mouse fibroblasts. Int J Radiat Biol 1995;68(2):205&#x2013;213. <pub-id pub-id-type="pmid">7658146</pub-id></citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nordsmark</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Overgaard</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer</article-title>
          <source>Acta Oncol</source>
          <year>2004</year>
          <volume>43</volume>
          <issue>4</issue>
          <fpage>396</fpage>
          <lpage>403</lpage>
          <pub-id pub-id-type="doi">10.1080/02841860410026189</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Nordsmark M, Overgaard J. Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer. Acta Oncol 2004;43(4):396&#x2013;403. <pub-id pub-id-type="pmid">15303502</pub-id></citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rofstad</surname>
              <given-names>EK</given-names>
            </name>
            <name>
              <surname>Sundfor</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Trope</surname>
              <given-names>CG</given-names>
            </name>
          </person-group>
          <article-title>Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis</article-title>
          <source>Br J Cancer</source>
          <year>2000</year>
          <volume>83</volume>
          <issue>3</issue>
          <fpage>354</fpage>
          <lpage>359</lpage>
          <pub-id pub-id-type="doi">10.1054/bjoc.2000.1266</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Rofstad EK, Sundfor K, Trope CG. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer 2000;83(3):354&#x2013;359. <pub-id pub-id-type="pmid">10917551</pub-id></citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yokoi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Fidler</surname>
              <given-names>IJ</given-names>
            </name>
          </person-group>
          <article-title>Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine</article-title>
          <source>Clin Cancer Res</source>
          <year>2004</year>
          <volume>10</volume>
          <issue>7</issue>
          <fpage>2299</fpage>
          <lpage>2306</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-03-0488</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Yokoi K, Fidler IJ. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res 2004;10(7):2299&#x2013;2306. <pub-id pub-id-type="pmid">15073105</pub-id></citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koch</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mayer</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Honecker</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Schittenhelm</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bokemeyer</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro</article-title>
          <source>Br J Cancer</source>
          <year>2003</year>
          <volume>89</volume>
          <issue>11</issue>
          <fpage>2133</fpage>
          <lpage>2139</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.bjc.6601375</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Koch S, Mayer F, Honecker F, Schittenhelm M, Bokemeyer C. Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro. Br J Cancer 2003;89(11):2133&#x2013;2139. <pub-id pub-id-type="pmid">14647149</pub-id></citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scheurer</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Rybak</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Rosli</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Neri</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Elia</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: a transcriptomic and proteomic study</article-title>
          <source>Proteomics</source>
          <year>2004</year>
          <volume>4</volume>
          <fpage>1737</fpage>
          <lpage>1760</lpage>
          <pub-id pub-id-type="doi">10.1002/pmic.200300689</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Scheurer SB, Rybak JN, Rosli C, Neri D, Elia G. Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: a transcriptomic and proteomic study. Proteomics 2004;4:1737&#x2013;1760. <pub-id pub-id-type="pmid">15174142</pub-id></citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pitt</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Nakeeb</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Abrams</surname>
              <given-names>RA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Perihilar cholangiocarcinoma: postoperative radiotherapy does not improve survival</article-title>
          <source>Ann Surg</source>
          <year>1995</year>
          <volume>221</volume>
          <issue>6</issue>
          <fpage>788</fpage>
          <lpage>798</lpage>
          <pub-id pub-id-type="doi">10.1097/00000658-199506000-00017</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Pitt HA, Nakeeb A, Abrams RA et al. Perihilar cholangiocarcinoma: postoperative radiotherapy does not improve survival. Ann Surg 1995;221(6):788&#x2013;798. <pub-id pub-id-type="pmid">7794082</pub-id></citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>